Sino Biopharm gets approval for hemophilia treatment in China

Sino Biopharmaceutical Limited announced that its self-developed "Recombinant Human Coagulation Factor VIIa N01 for Injection," branded as Anqixin®, has been approved for marketing by China's National Medical Products Administration. This drug is indicated for treating bleeding episodes in adult and adolescent hemophilia patients with inhibitors to coagulation factors VIII or IX. Anqixin® is the first domestically produced recombinant human coagulation factor VIIa-type biological product approved in China.